Editas Medicine (EDIT) EBIT Margin (2015 - 2025)
Editas Medicine (EDIT) posted quarterly EBIT Margin of 325.44% for Q3 2025, up 10732374.0% year-over-year from N/an in Q3 2024, and up 77.41% quarter-over-quarter from 1440.58% in Q2 2025.
Powered by 
Analysis
Editas Medicine (EDIT) EBIT Margin (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported EBIT Margin for 11 consecutive years, with 325.44% the latest figure, recorded in Q3 2025.
- In Q3 2025, EBIT Margin rose 10732374.0% year-over-year to 325.44%; the TTM figure through Sep 2025 stood at 428.71% (down 5868.0% YoY), while the FY2024 annual figure was 777.22%, down 56067.0% from the prior year.
- EBIT Margin improved to 325.44% in Q3 2025 per EDIT's latest filing, from 1440.58% in the prior quarter.
- Across five years, EBIT Margin topped out at 39.9% in Q4 2023 and bottomed at 136952.38% in Q3 2022.
- Historically, EBIT Margin has averaged 15270.04% across 5 years, with a median of 940.09% in 2023.
- Annual changes were most pronounced in 2022 — EBIT Margin slumped 13631896 bps — and 2023, when it surged 13601229 bps.
- Editas Medicine's EBIT Margin stood at 333.71% in 2021, then sank by 191 bps to 970.72% in 2022, then soared by 96 bps to 39.9% in 2023, then slumped by 282 bps to 152.24% in 2024, then sank by 114 bps to 325.44% in 2025.
- Business Quant data shows EDIT's EBIT Margin at 325.44% in Q3 2025, 1440.58% in Q2 2025, and 1635.1% in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -325.44% |
| Jun 30, 2025 | -1,440.58% |
| Mar 31, 2025 | -1,635.10% |
| Dec 31, 2024 | -152.24% |
| Sep 30, 2024 | -107,649.18% |
| Jun 30, 2024 | -14,016.18% |
| Mar 31, 2024 | -5,902.29% |
| Dec 31, 2023 | -39.90% |
| Sep 30, 2023 | -940.09% |
| Jun 30, 2023 | -1,527.33% |
| Mar 31, 2023 | -517.32% |
| Dec 31, 2022 | -970.72% |
| Sep 30, 2022 | -136,952.38% |
| Jun 30, 2022 | -852.47% |
| Mar 31, 2022 | -749.52% |
| Dec 31, 2021 | -333.71% |
| Sep 30, 2021 | -633.42% |
| Jun 30, 2021 | -14,617.68% |
| Mar 31, 2021 | -875.26% |
| Dec 31, 2020 | -576.86% |